Inhibition of Melanin Formation by Chemical Agents  by Denton, Cleveland R. et al.
INHIBITION OF MELANIN FORMATION BY CHEMICAL AGENTS
CLEVELAND H. DENTON, M.D., AARON BUNSEN LERNER, M.D. AND THOMAS
B. FITZPATRICK, M.D.
Physicians and laity alike have long been interested in depigmentation of the
skin by chemical agents. It has been hoped that these substances might be use-
ful in the treatment of patients having various forms of disfiguring hyperpig-
mentation.
Ointments of mercury compounds probably have been used longer and more
frequently than other substances to produce depigmentation. Their use as
"freckle creams" has been persistent despite the inconclusive results produced.
Vitamin C in large oral doses decreases the pigmentation of some patients with
Addison's disease (1, 2, 3). Recently Schuppli (4) reported depigmenting scars,
chloasma, and chloasma-like dermatoses with the use of iontophoretic applica-
tion of ascorbic acid. During the past 15 years several reports have appeared
showing that hydroquinone and two other p-hydroxyphenyl derivatives inhibit
melanin formation in mammals. Other chemicals which inhibit pigment forma-
tion have been discussed in detail recently (5). When the different inhibitors of
melanin formation are compared with each other, it is apparent that at the
present time the p-hydroxyphenyl derivatives probably offer the best means of
effecting depigmentation of the skin. These chemicals shown in Fig. 1 are hydro-
quinone, monobenzylether of hydroquinone and p-hydroxypropiophenone. Be-
cause of this similarity in structure, it was believed worthwhile to compare these
three compounds experimentally. In this report the inhibition of pigmentation
by hydroquinone, monobenzylether of hydroquinone and p-hydroxypropiophe-
none will be reviewed; and recent studies with these compounds will be presented.
Hydroquinone. Oettel (6) reported in 1936 that when hydroquinone was fed to black
haired cats in doses of 30 mg. per kilogram daily over a period of six to eight weeks, the
hair turned gray. In a similar period after stopping the drug the hair become repigmented.
Martin and Ansbacher (7) confirmed Oettel's finding and reported in addition that young
mice given hydroquinone in their feedings developed achromatrichia within a period of
from four to twenty weeks.
Monobenzylet her of hydroquinone. Oliver, Schwartz, and Warren (8) first reported in 1939
that an antioxidant known by the trade name of Agerite AIba* in rubber gloves was respon-
sible for depigmentation of the skin of workers wearing the gloves. This preliminary report
was followed in 1940 with publications by the same authors (9, 10) giving a detailed study
of the clinical and pathological characteristics of the effect of monobenzylether of hydro-
quinone on skin. Spencer (11, 12) has reported leukoderma occurring also from rubber
used in covering wire dish trays, adhesive tape, hat bands, and from washing contraceptive
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diaphragms. Botvinick (13) reported a case of dermatitis and secondary leukoderma due
to fabric-lined rubber gloves. Bernstein and Sachs (14) observed cases of leukoderma arising
from contact during the manufacturing process of rubber dolls and the synthetic rubber,
neoprene. All of the above materials were found to contain or assumed to contain mono-
benzylether of hydroquinone.
Peck and Sobotka (15) fed a number of guinea pigs approximately 12 grams of mono-
benzylether of hydroquinone over a period of five months with no pigmentary changes
being noted. However, the local application of the compound over a period of months
caused depigmentation of the epidermis. The hair bulbs were not affected.
Para-hydroxypropiophenone. In 1949, Perrault and co-workers (16) noted variable success
in the treatmel3t of hot flashes with the oral use of p-hydroxypropiophenone (11-365,
Frénateur Hypophysaire de Synthèse). These workers then tried the drug in a case of
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malignant chorioepithelioma with pulmonary metastases. Six months later the patient was
apparently cured as indicated by clinical, biological, and radiological studies. In addition,
there was no recurrence eight months following termination of therapy. The compound was
successfully employed in the treatment of toxic diffuse goiter and malignant exophthalmus,
especially in those cases with a strong hypophyseal influence. The drug was reported to be
effective in cases of ovarian and hypophyseal-ovarian dysfunction. In 1950, Perrault (16)
summarized the studies regarding p-hydroxypropiophenone and indicated that the com-
pound had no direct cellular effect and that its action was probably through hypophyseal
inhibition.
Grupper, Plas, and Boudin (17) cited evidence indicating that Riehl's melanosis might be
due to pituitary dysfunction. This belief was further borne out by reference to the favorable
influence on Riehl's melanosis by x-ray therapy directed to the pituitary. With these con-
cepts in mind they treated five cases of Riehl's melanosis with p-hydroxypropiophenone in
dosage of 1—2 Gm. daily for four to six weeks with success. In a subsequent report Grupper
and Plas (18) reported the successful treatment of a total of eight cases of Riehl's melanosis,
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two eases of chloasma, a case of cervico-facial pigmentation, and two cases of erythrose
peribuccale pigmentaire de Brocq. Perrault (16) cited two cases of Riehi's melanosis treated
with p-hydroxypropiophenone in which he obtained success in one and failure in the other,
possibly on the basis of insufficient dosage.
Para-hydroxypropiophenone was studied during a search for synthetic estrogen-like
compounds. It has a chemical structure much like diethylstilbesterol (Fig. 2) but seems to
lack its estrogenic and melanin influencing properties according to Perrault (16).
EXPERIMENTAL STUDIES
The experiments were divided into three groups as follows: 1) In vitro studies
to determine the effect of p-hydroxyphenyl derivatives on the enzymatic forma-
tion of melanin from tyrosine and dopa. 2) Studies on the effect of oral and
parenteral administration of these compounds to pigmented guinea pigs and
mice. 3) Studies on the effect of local application of these agents to human skin.*
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In vitro .tudies. The effect of p-hydroxyphenyl derivatives on the enzymatic
oxidation of tyrosine and dopa to melanin was studied using tyrosinase from the
Harding-Passey mouse melanoma (19). Detailed reports of these investigations
will be published elsewhere. Hydroquinone, monobenzylether of hydroquinone
and p-hydroxypropiophenone were added to tyrosine-tyrosinase and dopa-tyro-
sinase reaction mixtures. Hydroquinone in 12 times the molar concentration of
tyrosine completely inhibited melanin formation as determined by measurements
of oxygen uptake and quantitative analyses of unreacted tyrosine at the end of
the reaction. No inhibition occurred when dopa was used as substrate. These
findings show that hydroquinone inhibits the first step in melanogenesis, that is,
the conversion of tyrosine to dopa, Fig. 3.
Para-hydroxypropiophenone in 9.7 times the concentration of tyrosine pro-
longed the induction period of tyrosine oxidation. There was no effect on dopa
* Reagent grade Eastman hydroquinone and p-hydroxypropiophenone were used.
Monobenzylether of hydroquinone was prepared by recrystallizing the commercial grade
chemical with 40 per cent methanol.
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oxidation. Here, as in the case of hydroquinone, p-hydroxypropiophenone in-
hibits only the conversion of tyrosine to dopa.
Monobenzylether of hydroquinone in 3.6 times the concentration of tyrosine
stimulated the reaction. The induction period in tyrosine oxidation was reduced,
and monobenzylether of hydroquinone was oxidized. That is, the oxygen uptake
of the tyrosine-tyrosinase monobenzylether of hydroquinone reaction mixtures
was much greater than that of the control tyrosine-tyrosinase preparation. Mono-
benzylether of hydroquinone also increased the oxygen uptake of the dopa-tyro-
sinase reaction. Since tyrosinase does not catalyze the oxidation of mono-
benzylether of hydroquinone, this compound must be oxidized by chemicals
formed when dopa is oxidized to melanin. It cannot be determined from these
studies how monobenzylether of hydroquinone inhibits melanin formation. It is
possible that in the skin this compound is converted to hydroquinone which then
TABLE I
Effect on pigmentation of male guinea pigs after daily oral administration of p-hydroxyphenyl
derivatives for 76 days
Five guinea pigs (average weight 564 g./animal) were used in each group.
COMPOSYND DAILY DOSE
mg./kg./day
OT oT
(grams)
NUMBER OF ANIMALS
SROWCNGDEPIGMEN-
Hydroquinone
Monobenzylether of hydroquinone
p-Hydroxypropiophenone
None
22 —' 88
40 —+ 160
30 — 120
2.38
4.37
3.23
1?
3
2
0
inhibits the reaction. It is also possible that the compound produces depigmenta-
tion through its action as a reducing agent so that melanin is reduced to a light-
colored substance. A third hypothesis is that monobenzylether of hydroquinone
acts as an anti-oxidant to prevent oxidation of sulfhydryl groups, thereby making
more sulfhydryl groups available for tyrosinase inhibition. However, this hy-
pothesis is not supported by our experimental work (20).
Animal tests. Three groups of five adult male guinea pigs were fed capsules of
increasing amounts of hydroquinone, monobenzylether of hydroquinone, and
p-hydroxypropiophenone daily for 76 days. A fourth group was used as a control.
Since we had no information on the toxicity of these compounds, the animals
were given an arbitrary initial dose as shown in Table I. The chemicals did not
produce any toxic reaction, and the dose was rapidly increased to the level indi-
cated in Table I. Again no toxic effects were noted, and it i believed that the
highest dose finally used could have been employed from the onset of the experi-
ment. None of the control group exhibited depigmentation. Depigmentation,
when occurring, was first evident after four weeks of treatment; and it became
more marked from then on throughout the experimental period of 76 days.
One of the hydroquinone-treated animals showed questionable depigmenta-
tion, three of the monobenzylether of hydroquinone group (Figs. 4 & 5) became
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lighter, and two of the p-hydroxypropiophenone group (Figs. 6 & 7) turned
lighter. In general it appeared that very light colored or black guinea pigs showed
the greatest change in color. The dark brown guinea pigs showed no change.
FIG. 4. Guinea pig prior to oral administration of monobenzylether of hydroquinosie.
FIG. 5. Guinea pig following 76 days of oral administration of monohenzylether of hydro-
quinone.
In the case of the guinea pigs rcceiving monohenzylether of hydroquinone the
results varied from those of Peck and Sobotka (15), who found no pigmentary
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change in guinea pigs fed a similar daily dose over a five-month period. This
might be accounted for by the use of different strains of guinea pigs. In addition
it is possible that our final doses per kilogram per day may have been higher
than those used by Peck and Sobotka.
Fin. 6. Guinea pig prior to oral administration of para-hydroxypropiophenone.
Fio. 7. Guinea pig following 76 days of oral administration of para-hydroxypropiophenone.
Another experiment was conducted using four groups of four adult black
C-57 male mice. These animals were observed over a 76-day period for pig-
mentary change in their hair. One group was given daily 0.05 mL subcutaneous
-
-
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injections of hydroquinone in water in doses of 22 mg. per kilogram. Another
group was given similar injections of p-hydroxypropiophenone in propylene
glycol in doses of 30 mg. per kilogram—a dose comparable to that used by
Grupper and coworkers (17) (1—2 Gm. per day in adults). The fourth group was
given hydroquinone in their drinking water in increasing doses from 37 to 262
mg. per kilogram per day. As noted in Table II the hydroquinone group showed
marked depigmentation at the site of injection (Figs. 8 & 9). The p-hydroxy-
propiophenone group showed no local depigmentation, but there was noted a
diffuse increase in the number of grey hairs throughout the body hair. The group
receiving hydroquinone in the drinking water showed only questionable pig-.
mentary change compared to the control group over the period of observation.
When the study was repeated using 7-week old male C-57 black mice, it was
found that 2 out of 4 mice showed some general depigmentation. The results of
TABLE II
Effect on pigmentation of black C-.57 male mice after daily administration of p-hydroxyphenyl
derivatives for 76 days
Four mice 7 months old of approximately 20 g. average weight were used in each group,
COMPOUND ADMINISTRATION F IL DOSE
mg/kg/day
22
TOTAL
33.3
DEPIGMENTATION OF HAIR
At site of injectionHydroquinone in water. 0.05 ml. subcut.
p-Hydroxypropiophe-
none in propylene gly-
col 0.05 ml. subcut. 30 45.6 Generally over body
Propylene glycol con-
trol 0.05 ml. subcut. None
Hydroquinone Orally in drinking 37 262 247 None
water
oral administration of hydroquinone to black mice seem to depend on some un-
known factor associated with the age of the mice. However, injections of hydro-
quinone consistently produced depigmentation at the site of injection—probably
as a result of the great concentration of hydroquinone in the injection area. As
in the case of the guinea pigs, depigmentation, when it occurred, was first ob-
served after about 4 weeks and became more marked as the experiment pro-
gressed. These results were in general agreement with the finding of Martin and
Ansbacher (7) that young mice given hydroquinone orally developed achromo-
trichia in an interval of from four to twenty weeks.
Two of the 4 adult mice and all 4 young mice receiving hydroquinone in the
drinking water developed alopecia on the back of the neck during the course of
the experiments.
Clinical studies. After it was shown that monobenzylether of hydroquinone
(Agerite. Alba) would produce depigmentation, it. was only natural that the
material should be suggested for clinical trial in cases of hyperpigmentation
(8, 9, 21). Oliver and coworkers (8) first pointed out that in the clinical use of
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this chemical, one should take into account the facts that it requires a long time
for depigmentation to occur, that there is a possibility of depigmenting a larger
area than desired, and that sensitization to the compound may occur. Although
FIG. 8. Black male C-57 control mouse.
FIG. 9. Black male C-57 mouse showing depigmentation of hair at site of subcutaneous
injection of hydroquinone.
these precautions must be kept in mind, they should not prevent the careful
clinical use of monobenzylether of hydroquinone. This view is supported by the
following studies on clinical cases.
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Normal subjects. Continuous patch tests of ten and thirty per cent hydro-
quinone, monobenzylether of hydroquinone, and p-hydroxypropiophenone in
yellow petrolatum were applied to the backs of seven young adults for thirty
days. Four of the subjects were Negro males, one was a Negro female, and two
were white males with freckles. As noted in Table II two of the Negro subjects
developed depigmentat ion from hydroquinone and monobenzylethcr of hydro-
Fio. 10. Sites of continuous patch tests on back of a Negro male volunteer. From above
downwards, the patches are para-hydroxypropiophenone, hydroquinone, and monobenzyl-
ether of hydroquinone. Ointments containing 10 per cent of the chemicals are on the left,
and those containing 30 per cent are on the right.
quinone. The higher concentration of these substances gave increased depig-
mentation (Fig. 10). Following the termination of the experiment, pigmentation
gradually returned about the hair follicles in all areas of depigmentation after
one month. These findings in the case of monohenzylether of hydroquinone
paralleled those of Oliver and coworkers (8, 9, 10). In two of the Negro volun-
teers there was dermatitis due to the hydroquinone. There was no reaction from
monobenzylether of hydroquinone. There was neither dermatitis nor evidence
of depigmentation from the patches of p-hydroxypropiophenone during the
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period of observation. It is possible that if the ointments had been applied for a
longer period of time more cases would have shown depigmentation.
Twenty per cent monobenzylether of hydroquinone in a special vanishing
cream base* was applied to the forearms of 70 normal individuals as a patch test
for 48 hours. No case of sensitivity was noted over the test period. These results
indicate that the preparation is satisfactory for general clinical use.
Pigmentary Disorders
Case 1. D. P., a white male age 24, with generalized lentigenes and psychoneurosis,
developed pigmented cutaneous macules on the exposed and unexposed surfaces of the body
at 2—3 years of age. These lesions were more prominent in the summer. At the age of 15, the
lesions became much darker and more numerous. It was at this time that the patient had
mumps followed by atrophy of the right testicle. There was no familial history of pigmen-
tary disturbances. The patient developed a psychoneurosis in addition to having pigmen-
tary changes.
General physical examination was essentially negative except for atrophy of the right
testicle. Over the skin surface including the lips there were many hyperpigmented macules
varying in diameter from 0.5 mm. to 3 mm. being most abundant on the exposed surfaces of
the body. In some areas these lesions coalesced to form macules which were 3 to 7 cm. in
diameter.
Laboratory reports were within normal limits. X-ray examination of the gastrointestinal
tract for polyposis was negative. The skin biopsy of one of the lesions was characteristic of
lentigo on microscopic examination.
In May 1950, when this patient presented himself to the Mayo Clinic for the treatment
of his pigmented lesions, it was suggested by one of us (T. B. F.) that he be treated with
monobenzylether of hydroquinone. Since then the patient has been consistently applying
33 per cent monobenzylether of hydroquinone in petrolatum and more recently in an al-
cohol-acetone lotion to the face, neck, and one hand one or two times daily. He has shown
marked improvement of the areas treated (Figs. 11 & 12). This is also evident when the
treated hand is compared with the untreated hand. There has been no dermatitis and the
patient is very pleased with the result.
Case 2. B. H., a white male age 24, with generalized lentigenes and psychoneurosis.
This patient's early history is obscure; but apparently at the age of 3—4 years, he developed
swelling of the face and neck which lasted for some time. This disturbance was followed by
pigmented lesions on his skin, the initial site being unknown. At the age of 8, the patient
became aware of the lesions and he felt that many more lesions appeared over his body at
that age. Since then the lesions apparently have not increased either in number or in size.
The lesions become darker on exposure to sunlight. There was no history of ingestion of
heavy metals. The family history was of interest in that the patient's mother died of a tumor
of the eye with metastases to the liver at age 55; two full brothers have epilepsy, one being
a mental patient; one maternal half-brother is described as nervous; and one paternal half-
sister has a nervous tic. The patient has a psychoneurosis.
General physical examination was essentially normal. Over the patient's skin surface
were many macular brown and black lesions varying in size from 0.1—1.5 cm. in diameter.
The mucous membranes were clear and the eye grounds showed no abnormal pigmentation.
Laboratory reports were within normal limits. X-ray examination of the gastrointestinal
tract for polyposis was negative. The skin biopsy of one of the lesions was characteristic of
lentigo on microscopic examination.
* This material was supplied through the courtesy of Paul B. Elder Company, Bryan,
Ohio.
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This patient applied 33 per cent monobenzylether of hydroquinone in yellow petrolatum
and in alcohol-acetone lotion to the face, neck, and hands intermittently for a period of
six months. He cooperated poorly with the treatment and there was only slight decrease in
pigmentation. There was no dermatitis.
Case 3. L. E., white female age 32 with chloasma. The patient developed transitory
hyperpigmentation of the face 13 years ago during her first pregnancy. Two years later
with her second pregnancy she again developed hyperpigmentation over the face. This
darkening has increased in severity since that time.
Fin. 11. Case 1, prior to the local application of 33 per cent monobenzylether of hydro-
quinone to the face.
General physical examination was essentially normal. Over the chin, cheeks, and fore-
head there was a circular band of well marginated hyperpigmentation with adjacent areas
of hypopigmentation.
Basal metabolic rate was —19 per cent. Other laboratory reports were within normal
limits.
The patient has consistently applied 30 per cent monobenzylether of hydroquinone in a
vanishing cream to the lesions twice daily for thirty days. She noted a burning sensation
lasting for thirty minutes after the preparation was applied. However, this feeling has been
diminishing lately. The patient has shown definite lightening of her lesions after one month
of therapy. There has been no dermatitis.
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Case 4. N. S., a white female age 35, with Berloek dermatitis of the face. Thirty-three
per cent monobenrylether of hydroquinone in yellow petrolatnm was applied daily to the
face for a period of two months with no evidence of depigmentation or dermatitis. Therapy
is being continued.
Case 5. J. H., a white male age 25, with a macular pigmented nevus of the face. Thirty-
three per cent monobenzylether of hydroquinone in yellow petrolatum was applied to the
lesion daily for a period of two months with resulting depigmentation. Occasionally there
was evidence of slight dermatitis during therapy.
Fm. 12. Case 1, following the local application of 33 per cent monobenzylether of hydro-
quinone to the face twice daily for eight months.
Case 6. F. Z., a white male age 31, with Ttiehl's melanosis of the face. Thirty per cent
monobenzylether of hydroquinone in a vanishing cream base was applied twice daily for
six weeks. To date there has been no change in pigmentation and no dermatitis. Therapy is
being continued.
Case 7. A. L., a white male age 30, with ephelides of the arms. Thirty per cent mono-
benzylether of hydroquinone in a vanishing cream base was applied twice daily for three
weeks. There has been some depigmentation, but pruritus and secondary liehenification
from scratching in the treatment area occurred. Therapy has been stopped.
In addition to the above cases, nine more patients with various disorders of
hyperpigmentation are being treated at the present time with 20 to 30 per cent
monobenzylether of hydroquinone in a vanishing cream base applied twice
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daily. While there has been no clinical follow-up as yet, we have not been notified
of the occurrence of dermatitis. The accomplishment of depigmentation with
the lack of dermatitis by the use of this compound is in accord with the findings
of Oliver, Schwartz, and Warren (8) and Pollock (21).
Various bases and solvents for monobenzylether of hydroquinone were tried.
It was decided that the most satisfactory preparations were a lotion (acetone
seven parts and alcohol ten parts), a vanishing cream base, and yellow petrola-
tum, each containing 10 to 33 per cent monobenzylether of hydroquinone. When
the lotion is used, the solvent quickly evaporates; and a very fine flesh colored
powder of the compound remains on the treated area. This powder is not objec-
tionable and often serves as an acceptable cosmetic covering for the lesions under
treatment. The ointments are not particularly greasy and they remain very
smooth. The lotion and the ointment preparations can be used together, the
lotion during the day and the ointment at night.
Stolar (22) has had wide experience in treating cases of abnormal pigmenta-
tion with monobenzylether of hydroquinone. He found that when wetting agents
are incorporated into the ointment, depigmentation extends beyond the area of
application. In the preparations we used depigmentation occurred only at the
site where the ointment was applied.
We have had no clinical experience with the oral use of p-hydroxypropiophe-
none in cases of hyperpigmentation. However, we hope to undertake a detailed
clinical study of this compound in the near future.
DISCUSSION
It is of interest to compare the mechanism of melanin inhibition effected by
the three types of compounds which have been used clinically to depigment skin,
namely, mercury compounds, ascorbic acid and p-hydroxyphenyl derivatives.
Nealon (23) found that mercury preparations could decrease the color of skin
by as much as 15 per cent. Darkly pigmented people showed the greatest change.
However, in general it is not believed that these ointments are very effective
depigmenting agents. Some dermatologists believe that mercury preparations
act merely by producing an exfoliation which in turn causes depigmentation.
This explanation is probably incorrect because many agents other than mercury
compounds produce exfoliation without lightening of the skin color. A more
plausible hypothesis is that mercury may replace the copper required for tyro-
sinase activity and thereby inactivate the enzyme. This concept is supported by
recent in vitro experiments in which it was shown that mercury ions could com-
pete with cupric ions for the active centers on tyrosinase (20). When mercury
ions became bound to the enzyme an inactive preparation was obtained.
Ascorbic acid acts in a different manner to decrease the color of skin. Melanin
pigment can exist in an oxidized or reduced state. In the oxidized state melanin
is very dark, while in the reduced state it is light brown in color. Ascorbic acid
can keep melanin in the reduced light colored form (3). In addition, ascorbic acid
can inhibit melanin formation by preventing the oxidation of dopa quinone, an
intermediate in the conversion of tyrosine and dopa to melanin. In all these
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actions the effect of ascorbic acid is oniy temporary. Pigmentation returns upon
discontinuation of the drug.
Para-hydroxyphenyl derivatives inhibit melanin formation in still another
way. Hydroquinone and p-hydroxypropiophenone inhibit the enzymatic oxida-
tion of tyrosine to dopa; that is, these compounds inhibit the first reaction of
melanogenesis. The details of this inhibition are not known at the present time.
These compounds may also serve as reducing agents to decrease skin color in a
manner similar to the action of ascorbic acid. Hydroquinone is not a useful in-
hibitor of pigment formation clinically for two reasons. First, when applied
locally to skill its action is weak and inconsistent because it is water soluble and
probably cannot penetrate the skin surface to exert its effect. Second, hydro-
quinone is unstable and undergoes auto-oxidation to form deeply colored prod-
ucts. When hydroquinone is applied to the skin these darkly colored products
form and adhere to the skin surface. Para-hydroxypropiophenone has little local
action but is effective when used orally or parenterally. It is possible that p-hy-
droxypropiophenone may act indirectly through the pituitary gland to decrease
melanin formation in addition to inhibiting the enzymatic formation of melanin.
The mechanism of action of monobenzylether of hydroquinone remains obscure.
This compound has no effect on the in vitro enzymatic oxidation of tyrosine or
dopa to melanin. It is possible that monobenzylether of hydroquinone is con-
verted to hydroquinone in the skin and that the hydroquinone formed prevents
melanin formation. It is also possible that monobenzylether of hydroquinone
can act as a reducing agent merely to maintain melanin in its lighter color. How-
ever, monobenzylether of hydroquinone does not act only as a reducing agent
because some cases of occupational leukoderma resulting from contact with this
chemical do not repigment completely upon cessation of exposure. Not all pa-
tients treated with monobenzylether of hydroquinone show depigmentation.
Definite variations exist from person to person. It is not known whether this
variability is due to differences in pH, hormonal activity, or differing enzyme con-
centrations in individual skins.
From the foregoing data as well as the reports of other investigators, it is evi-
dent that the hydroquinone derivatives, monobenzylether of hydroquinone and
p-hydroxypropiophenone, are effective clinical agents for treating hyperpig-
mentation due to melanin. These agents are more effective and more useful than
other agents used to date. When properly employed in 10 to 33 per cent concen-
tration in lotions or ointments, monobenzylether of hydroquinone is a valuable
local therapeutic agent. Undesirable side reactions such as dermatitis or sensi-
tization do not preclude its controlled medical use. No serious side reactions
have been encountered.
SUMMARY
1. It has been shown through clinical trial, animal experiments, and in vitro
studies that hydroquinone and p-hydroxypropiophenone are effective inhibitors
of melanin formation. Monobenzylether of hydroquinone was the most effective
inhibitor of melanin formation clinically, although it had no effect on melanin
formation in vitro.
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2. These compounds when administered orally to colored guinea pigs produce
depigmentation.
3. The parenteral administration of hydroquinone and p-hydroxypropiophe-
none to black mice also produces depigmentation.
4. Monobenzylether of hydroquinone in 10 to 33 per cent concentration in
lotions and ointments is an effective agent clinically for treatment of melanin
hyperpigmentation.
5. The mechanism of action of these compounds has been discussed.
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DISCUSSION
DR. PETER FLESCH: I would like to call Dr. Denton's attention to a recent
paper by Foster (Proc. U. S. Nat. Acad. Sci., 36, 606, 1950) who claims that
there is a non-enzymatic conversion of tyrosine and of dopa in normal mouse
skin. Unfortunately, it is impossible to evaluate this paper, because of lack of
detailed experimental data. If Foster's findings should be confirmed, the mecha-
nism of hydroquinone inhibition, as proposed by Dr. Denton, will have to be
reexamined.
DR. ROTHMAN: I wonder whether p-hydroxypropiophenone can be classified
as a hydroquinone derivative as it does not have two hydroxyl groups in para-
position. The results presented here on the action mechanism of hydroquinone
mono-berizyl ether are identical with those presented here a year ago by Dr.
A. L. Lorincz (see J. Invest. Dermat. 15, 425, December 1950).
DR. IRVIN BLANK: I may not be justified in rising to discuss Dr. Denton's
paper because I shall not discuss the main body of the paper on pigmentation.
However, in the last minute of Dr. Denton's paper, and also in Dr. Stolar's
comment, there was a good deal of discussion of the cliincal use of benzyl hydro-
quinone for producing de-pigmentation of the skin.
In a study of rubber dermatitis which we have been conducting in Boston, we
have learned to have a rather healthy respect for this compound because of its
sensitizing properties. It is probable that there have not yet been enough pa-
tients tested to draw any statistical conclusions, but one patient out of twelve,
as in Dr. Denton's series, would indicate a rather high sensitization index.
I suspect this material can cause some rather bad sensitizations, and I think
it may be dangerous to use it indiscriminately for the purpose of producing de-
pigmentation.
Dn. DENTON: In regard to the existence of tyrosinase in pigmented mouse
skin we believe that all the studies reported show that the enzyme is present
in that tissue.
For the treatment of our cases of hyperpigmentation we use a 20—30% concen-
tration of monobenzylether of hydroquinone. A vanishing cream base works
best for the ointment preparation. We found that a lotion consisting of ten parts
of alcohol and seven parts of acetone with 20% monobenzylether of hydro-
quinone is also satisfactory.
Sensitivity is a consideration with the use of any local therapy particularly
where a favorable cosmetic result is desired. Information gained from patch
testing and clinical experience indicates that the preparations give a low inci-
dence of sensitization.
